healthgevity bpc-157 BPC+PEA 500 – Regeneration or Risk? A Narrative

[DOI] [PubMed] [Google Scholar] Gunion MW, Tach Y

Pentadecapeptide BPC 157 reduces bleeding time and thrombocytopenia after amputation in rats treated with heparin, warfarin or aspirin

This product is supplied strictly for laboratory research purposes only and is not approved for human or veterinary use.

(8) The researchers also commented that introduction of the peptide appeared to have increased bone mineralization in the murine models subjected to a combination of Ipamorelin and catabolism-inducing agents, in contrast to the control group receiving only catabolism-inducing agents

When you swallow a tablet, it has to get through your digestive system first

Serious adverse events are extremely rare, with most subjects tolerating the peptide well throughout research protocols